Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Choudhary

Showing results (81-90 of 453) with videos related to

Pageof 46
Sort By:
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Biorxiv : the Preprint Server for Biology|October 20, 2022
Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 OmicronDa-Yuan Chen, Devin Kenney, Chue-Vin Chin, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic reboundDibya Ghimire, Chloe M Hasund, John Bianchi Colangeli, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Nature|January 11, 2023
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuationDa-Yuan Chen, Chue Vin Chin, Devin Kenney, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2021
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) SurvivalUpasana Das Adhikari, George Eng, Mara Farcasanu, et al.
Frontiers in Medicine|June 21, 2021
Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New YorkSantiago J Miyara, Lance B Becker, Sara Guevara, et al.
The International Journal of Angiology : Official Publication of the International College of Angiology, Inc|November 6, 2024
Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced MyelodysplasiaLuis F Morales, Santiago J Miyara, Sara Guevara, et al.
Pageof 46

Showing results (81-90 of 453) with videos related to

Sort By:
Pageof 46
The Journal of Infectious Diseases|May 8, 2024
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2Manish C Choudhary, Rinki Deo, Teresa H Evering, et al.
Biorxiv : the Preprint Server for Biology|October 20, 2022
Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 OmicronDa-Yuan Chen, Devin Kenney, Chue-Vin Chin, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2026
Post-infection immune response in adults with COVID-19 with and without nirmatrelvir-ritonavir treatment and virologic reboundDibya Ghimire, Chloe M Hasund, John Bianchi Colangeli, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Nature|January 11, 2023
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuationDa-Yuan Chen, Chue Vin Chin, Devin Kenney, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2021
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) SurvivalUpasana Das Adhikari, George Eng, Mara Farcasanu, et al.
Frontiers in Medicine|June 21, 2021
Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New YorkSantiago J Miyara, Lance B Becker, Sara Guevara, et al.
The International Journal of Angiology : Official Publication of the International College of Angiology, Inc|November 6, 2024
Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced MyelodysplasiaLuis F Morales, Santiago J Miyara, Sara Guevara, et al.
Pageof 46